Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Atezolizumab +1 More for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
Durham, North Carolina
This trial will investigate if adding atezolizumab to bevacizumab is a safe and effective treatment for patients with stage 4 EGFR mutant NSCLC whose cancer has progressed while taking osimertinib.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.